Consent given pursuant to Sections 14 and 14A for the importation and supply of the therapeutic goods specified by Aspen Pharma Pty Ltd

Overview

The Therapeutic Goods Act 1989, enacted by the Commonwealth Parliament, was introduced to regulate therapeutic goods in Australia, ensuring that they meet safety, quality, and efficacy standards. This Act provides the legal framework for the control of therapeutic goods, including medicines, medical devices, and blood products, through the Therapeutic Goods Administration (TGA). The policy objective behind the Act is to protect public health by ensuring that only therapeutic goods that meet the necessary standards are available for use. One instance of the Act’s application was the issuance of consent by the delegate of the Secretary of the Department of Health on 2 April 2015, allowing Aspen Pharma Pty Ltd to import and supply ethambutol hydrochloride under specific conditions due to non-compliance with certain labelling requirements. This consent, effective from 2 April 2015 until 30 April 2017, highlights the Act’s role in balancing public health protection with the practicalities of therapeutic goods supply.

Scope and Application

The Therapeutic Goods Act 1989, as amended, applies to the regulation of therapeutic goods in Australia, encompassing a wide range of products including medicines, medical devices, blood, and tissues. This Act provides the legislative framework for the Therapeutic Goods Administration (TGA) to ensure that therapeutic goods available in Australia are of acceptable quality, safety, and efficacy. The Act applies to entities such as manufacturers, importers, sponsors, and suppliers of therapeutic goods, and it governs their conduct and transactions related to these products. Geographically, the Act has a national reach, applying across the Commonwealth of Australia, including states, territories, and external territories. While the Act broadly applies to all therapeutic goods, certain exclusions and exemptions may apply, such as to goods that are for personal use, research purposes, or certain types of blood and tissues. The Act also provides for the creation of regulations and standards through subordinate instruments, which can extend or restrict its application by specifying detailed requirements or conditions for particular therapeutic goods or classes of goods.

Key Provisions

The Therapeutic Goods Act 1989, specifically in relation to sections 14 and 14A, grants the delegate of the Secretary of the Department of Health the authority to give consent for the importation and supply of therapeutic goods that do not fully comply with the applicable standards (section 14). In this instance, the delegate has authorised the importation and supply of ethambutol hydrochloride (MYAMBUTOL) 100 mg tablets by Aspen Pharma Pty Ltd, despite the product labels not meeting the criteria outlined in paragraphs 3(2)(a) and 3(2)(j) of the Therapeutic Goods Order No. 69, which pertains to the general requirements for medicine labels. This consent is effective from 2 April 2015 until 30 April 2017. The consent provided is contingent upon certain conditions, including the over-labelling of carton labels with the Australian sponsor’s details and the distribution of specific letters to healthcare professionals explaining the reasons for the UK-packaged stock supply. Under this Act, entities such as Aspen Pharma Pty Ltd must adhere to the conditions set by the delegate of the Secretary to ensure compliance with the Act while supplying non-compliant therapeutic goods. The primary obligations include ensuring that the carton labels are augmented with a sticker containing the Australian sponsor's name, address, and the AUST R number of the product. Additionally, a 'Dear Doctor' letter must be distributed broadly, while a 'Dear Pharmacist' letter must accompany each supply of the product. These letters must be identical to the ones submitted to the Therapeutic Goods Administration with the initial application and subsequent correspondence, providing clear information on the supply of UK-packaged stock. Failure to comply with the conditions set forth in the consent may lead to various consequences. While the Act does not explicitly state offences or penalties for non-compliance with the consent conditions, general provisions within the Act allow for enforcement actions. Non-compliance could result in regulatory action, including the potential for product recalls, fines, and other penalties as stipulated under the broader framework of the Therapeutic Goods Act 1989. The exact penalties would depend on the specific nature and severity of the non-compliance, with potential maximum penalties as outlined in other relevant sections of the Act.